Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study.

ABSTRACT:

Background

Antimicrobial resistance (AMR) is one of the most serious public health challenges worldwide, including in Japan. Globally, research and development of new antimicrobials has stalled due to unfavorable market conditions, which undervalue antimicrobials. Furthermore, Japan faces the additional challenge of delayed commercialization for a number of recently approved treatments.

Objective

This study aims to examine the impact on AMR of introducing a new anti-infective treatment, ceftazidime/avibactam, into current treatment strategies. It reports the resulting clinical and economic outcomes from the perspective of healthcare payers in Japan.

Methods

A previously published and validated dynamic disease transmission model was adapted to the Japanese setting. The

SUBMITTER: Matsumoto T 

PROVIDER: S-EPMC9476387 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature